CTLA4 and neoplasm: Currently, available CTLA-4-targeted ICIs, such as the humanized monoclonal antibody ipilimumab, block the CTLA-4-B7 pathway, enhancing effector T-cell proliferation and activation, thereby augmenting antitumor immune responses and tumor cell destruction (35, 36).